New TBVI senior leadership
The Governance Board of TBVI is pleased to announce the following senior leadership appointments: The Executive Director of TBVI is Dr Nick Drager, previously Chair of the TBVI Advisory [...]
24.6 million Euros for TB vaccine R&D
The TBVI consortium has been granted 24.6 million euros from the European Commission H2020 framework programme (€18.2 mln.) and several institutions as well as national governments outside the [...]
New training on adjuvants and vaccine formulation, deadline for submission 28 Feb
TBVI is partner in ADITEC, a project to advance new immunisation technologies. Partners of this consortium are presenting the fourth course on adjuvants and vaccine formulation. Dates: 15-19 June [...]